Search results
Showing 1276 to 1290 of 1766 results for patient safety
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
This indicator covers the percentage of women with epilepsy who are aged 18 or over, but under 45, who are taking antiseizure medications and have a record of being given information and advice in the previous 12 months about pregnancy or conception, or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM71
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
there is a relationship between midwifery staffing and maternal or neonatal safety outcomes, but the evidence was weak, potentially...
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)
Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.
View recommendations for HTG124Show all sections
Sections for HTG124
Evidence-based recommendations on corneal endothelial transplantation. This involves replacing only the innermost layers of the cornea with a healthy section from a donor eye without disturbing the overall structure.
View recommendations for HTG195Show all sections
Sections for HTG195
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .